ArticleHypertension research : official journal of the Japanese Society of Hypertension2025
Isolated diastolic hypertension and incident cardio-renal-metabolic multimorbidity in the Tehran Lipid and Glucose Study: comparison of ACC/AHA and ESC/NICE guideline definitions.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Blood pressure and renal function decline in apparently healthy adults: the tehran lipid and glucose study.Journal of human hypertension · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypertension is defined as ≥130/80 mm Hg by ACC/AHA 2017, and ≥140/90 mm Hg by the ESC 2018 and NICE 2019. We examined the association between isolated diastolic hypertension (IDH, by both thresholds) and cardio-renal-metabolic (CRM) multimorbidity. From 1999 to 2018, we followed 7377 (mean age: 37.7 years) and 6717 (36.8 years) Tehran Lipid and Glucose Study (TLGS) participants, initially free of cardiovascular disease (CVD), type 2 diabetes (T2DM), and chronic kidney disease, with systolic blood pressure (SBP) <140 and <130 mm Hg based on ESC/NICE and ACC/AHA criteria, respectively. Multivariable Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for CRM multimorbidity (coexistence of ≥2 of CVD, kidney function decline [KFD], and T2DM). IDH was identified in 28.2% of participants using ACC/AHA criteria and 5.9% using ESC/NICE criteria. Over a median 15.3-year follow-up (IQR: 12.1-16.6), 182 CRM multimorbidity events occurred per ACC/AHA IDH criteria and 241 per ESC/NICE criteria. In the fully adjusted model, IDH by ESC/NICE criteria was not significantly associated with CRM multimorbidity (HR: 1.45 [95% CI: 0.98-2.15]), while stage 2 IDH by ACC/AHA criteria showed a significant association (2.15 [1.21-3.82]). Similar associations of IDH with incident CRM multimorbidity were observed across age groups, sex, current smoking, obesity, dyslipidemia, and prediabetes. IDH was associated with increased risks of T2DM, CVD, and KFD as individual outcomes. In conclusion, stage 2 IDH per ACC/AHA criteria is linked to a higher risk of incident CRM multimorbidity, independent of SBP levels.
Indexed as
Identifiers
40595361What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.